Ftse Mib
35.108,74
0,49%
DAX
20.329,94
-0,10%
S&P 500
5.918,25
0,16%
NASDAQ
19.478,88
-0,06%
Bitcoin
94.442,90
-0,60%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Prothena Corporation PLC (PRTA) Prothena Corporation PLC (PRTA) Notizie

PRTA

Prothena (PRTA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRTA
DataOraFonteTitoloSimboloCompagnia
04/01/202501:45Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:PRTAProthena Corporation PLC
30/12/202422:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRTAProthena Corporation PLC
30/12/202422:05Business WireProthena Announces Board of Directors UpdateNASDAQ:PRTAProthena Corporation PLC
19/12/202407:05Business WireRoche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseNASDAQ:PRTAProthena Corporation PLC
13/11/202413:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:PRTAProthena Corporation PLC
12/11/202422:05Business WireProthena Reports Third Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
05/11/202422:05Business WireProthena to Report Third Quarter 2024 Financial Results on November 12NASDAQ:PRTAProthena Corporation PLC
04/10/202400:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
04/10/202400:57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PRTAProthena Corporation PLC
27/09/202422:05Business WireProthena Announces Leadership Team UpdatesNASDAQ:PRTAProthena Corporation PLC
29/08/202422:05Business WireProthena to Participate in Upcoming Healthcare ConferencesNASDAQ:PRTAProthena Corporation PLC
08/08/202423:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PRTAProthena Corporation PLC
08/08/202422:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRTAProthena Corporation PLC
08/08/202422:05Business WireProthena Reports Second Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/08/202422:05Business WireProthena to Report Second Quarter 2024 Financial Results on August 8NASDAQ:PRTAProthena Corporation PLC
28/05/202422:05Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationNASDAQ:PRTAProthena Corporation PLC
08/05/202422:05Business WireProthena Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
01/05/202422:05Business WireProthena to Report First Quarter 2024 Financial Results on May 8NASDAQ:PRTAProthena Corporation PLC
15/04/202422:05Business WireProthena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & LymphomaNASDAQ:PRTAProthena Corporation PLC
04/03/202422:05Business WireProthena Appoints David Ford to Newly Created Chief People Officer PositionNASDAQ:PRTAProthena Corporation PLC
22/02/202423:29Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PRTAProthena Corporation PLC
22/02/202422:56Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRTAProthena Corporation PLC
21/02/202422:05Business WireProthena Announces Appointment of Daniel G. Welch as Director and Chair DesignateNASDAQ:PRTAProthena Corporation PLC
15/02/202422:05Business WireProthena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
14/02/202418:16Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PRTAProthena Corporation PLC
14/02/202401:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRTAProthena Corporation PLC
08/02/202422:05Business WireProthena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024NASDAQ:PRTAProthena Corporation PLC
24/01/202422:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PRTAProthena Corporation PLC
08/01/202414:30Business WireProthena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio ProgramsNASDAQ:PRTAProthena Corporation PLC
02/11/202321:05Business WireProthena Reports Third Quarter 2023 Financial Results and Business HighlightsNASDAQ:PRTAProthena Corporation PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRTA

La tua Cronologia

TG
A2R73G
Glaxosmithkline
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network